(Q42994099)

English

Ethinylestradiol-chlormadinone acetate combination for the treatment of hirsutism and hormonal alterations of normal-weight women with polycystic ovary syndrome: evaluation of the metabolic impact

scientific article published in August 2010

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Ethinylestradiol-chlormadinone acetate combination for the treatment of hirsutism and hormonal alterations of normal-weight women with polycystic ovary syndrome: evaluation of the metabolic impact (English)

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

polycystic ovary syndrome

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

polycystic ovary

1 reference

based on heuristic

inferred from title

author name string

Maurizio Guido

1

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Daniela Romualdi

2

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Giuseppe Campagna

3

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Luigi Ricciardi

4

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Alessandro Bompiani

5

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Antonio Lanzone

6

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

publication date

1 August 2010

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Reproductive Sciences

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

17

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

8

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

767-775

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

A systematic review of commonly used medical treatments for hirsutism in women

1 reference

https://api.crossref.org/works/10.1177%2F1933719110371515

21 January 2018

Treatment of PCOS in adolescence

1 reference

https://api.crossref.org/works/10.1177%2F1933719110371515

21 January 2018

Sex hormone-binding globulin and female reproductive function.

1 reference

https://api.crossref.org/works/10.1177%2F1933719110371515

21 January 2018

Steroidal and non-steroidal factors in plasma sex hormone binding globulin regulation

1 reference

https://api.crossref.org/works/10.1177%2F1933719110371515

21 January 2018

Long-term health consequences of PCOS.

1 reference

https://api.crossref.org/works/10.1177%2F1933719110371515

21 January 2018

Acne resolution rates: results of a single-blind, randomized, controlled, parallel phase III trial with EE/CMA (Belara) and EE/LNG (Microgynon).

1 reference

https://api.crossref.org/works/10.1177%2F1933719110371515

21 January 2018

A 12-month evaluation of the CMA-containing oral contraceptive Belara: efficacy, tolerability and anti-androgenic properties

1 reference

https://api.crossref.org/works/10.1177%2F1933719110371515

21 January 2018

Efficacy of the low-dose combined oral contraceptive chlormadinone acetate/ethinylestradiol: physical and emotional benefits

1 reference

https://api.crossref.org/works/10.1177%2F1933719110371515

21 January 2018

Profile of the progesterone derivative chlormadinone acetate - pharmocodynamic properties and therapeutic applications

1 reference

https://api.crossref.org/works/10.1177%2F1933719110371515

21 January 2018

Chlormadinone acetate (CMA) in oral contraception--a new opportunity

1 reference

https://api.crossref.org/works/10.1177%2F1933719110371515

21 January 2018

Efficacy of an oral contraceptive containing EE 0.03 mg and CMA 2 mg (Belara) in moderate acne resolution: a randomized, double-blind, placebo-controlled Phase III trial.

1 reference

https://api.crossref.org/works/10.1177%2F1933719110371515

21 January 2018

The relation of the gonadotrophin response to chlormadinone according to body weight in patients with amenorrhea due to polycystic ovarian syndrome

1 reference

https://api.crossref.org/works/10.1177%2F1933719110371515

21 January 2018

Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS).

1 reference

https://api.crossref.org/works/10.1177%2F1933719110371515

21 January 2018

A new ultrasound criterion for the diagnosis of polycystic ovary syndrome: the ovarian stroma/total area ratio

1 reference

https://api.crossref.org/works/10.1177%2F1933719110371515

21 January 2018

Genotyping Steroid 21-Hydroxylase Deficiency: Hormonal Reference Data*

1 reference

https://api.crossref.org/works/10.1177%2F1933719110371515

21 January 2018

Clinical assessment of body hair growth in women

1 reference

https://api.crossref.org/works/10.1177%2F1933719110371515

21 January 2018

Decreased insulin removal contributes to hyperinsulinemia in obesity.

1 reference

https://api.crossref.org/works/10.1177%2F1933719110371515

21 January 2018

Assessment of insulin sensitivity in vivo

1 reference

https://api.crossref.org/works/10.1177%2F1933719110371515

21 January 2018

Impact of insulin and body mass index on metabolic and endocrine variables in polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1177%2F1933719110371515

21 January 2018

The mechanism of action of hormonal contraceptives and intrauterine contraceptive devices

1 reference

https://api.crossref.org/works/10.1177%2F1933719110371515

21 January 2018

Safety evaluation of modern oral contraceptives. Effects on lipoprotein and carbohydrate metabolism

1 reference

https://api.crossref.org/works/10.1177%2F1933719110371515

21 January 2018

Insulin receptors on monocytes and erythrocytes from obese patients.

1 reference

https://api.crossref.org/works/10.1177%2F1933719110371515

21 January 2018

A 1-year randomized study to evaluate the effects of a dose reduction in oral contraceptives on lipids and carbohydrate metabolism: 20 microg ethinyl estradiol combined with 100 microg levonorgestrel

1 reference

https://api.crossref.org/works/10.1177%2F1933719110371515

21 January 2018

Randomized controlled study of the influence of two low estrogen dose oral contraceptives containing gestodene or desogestrel on carbohydrate metabolism

1 reference

https://api.crossref.org/works/10.1177%2F1933719110371515

21 January 2018

Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society

1 reference

https://api.crossref.org/works/10.1177%2F1933719110371515

21 January 2018

Insulin sensitivity and lipid metabolism with oral contraceptives containing chlormadinone acetate or desogestrel: a randomized trial.

1 reference

https://api.crossref.org/works/10.1177%2F1933719110371515

21 January 2018

The effects of two monophasic oral contraceptives containing 30 mcg of ethinyl estradiol and either 2 mg of chlormadinone acetate or 0.15 mg of desogestrel on lipid, hormone and metabolic parameters

1 reference

https://api.crossref.org/works/10.1177%2F1933719110371515

21 January 2018

Effects of low dose oral contraceptives on very low density and low density lipoprotein metabolism

1 reference

https://api.crossref.org/works/10.1177%2F1933719110371515

21 January 2018

Noncontraceptive benefits of two combined oral contraceptives with antiandrogenic properties among adolescents

1 reference

https://api.crossref.org/works/10.1177%2F1933719110371515

21 January 2018

Progestogens with antiandrogenic properties

1 reference

https://api.crossref.org/works/10.1177%2F1933719110371515

21 January 2018

Evidence that chlormadinone acetate exhibits antiandrogenic activity in androgen-dependent cell line

1 reference

https://api.crossref.org/works/10.1177%2F1933719110371515

21 January 2018

Effectiveness of norgestimate and ethinyl estradiol in treating moderate acne vulgaris

1 reference

https://api.crossref.org/works/10.1177%2F1933719110371515

21 January 2018

The effects of chlormadinone acetate (CMA), antiandrogen, on the pituitary, testis, prostate and adrenal gland of the dog with spontaneous benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1177%2F1933719110371515

21 January 2018

Identifiers

10.1177/1933719110371515

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42994099&oldid=1976269398"